<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2012//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_120101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12605477</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>06</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1523-7060</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Mar</Month>
                        <Day>6</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Organic letters</Title>
                <ISOAbbreviation>Org. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unpredictable stereochemical preferences for mu opioid receptor activity in an exhaustively stereodiversified library of 1,4-enediols.</ArticleTitle>
            <Pagination>
                <MedlinePgn>633-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Using olefin cross-metathesis, we synthesized a novel stereodiversified library of compounds 3 containing a trans-1,4-enediol. Screening this library for mu opioid receptor (MOR) affinity identified multiple high-affinity ligands and revealed that the stereochemical configuration varied widely among those ligands having the highest affinity. It was not possible to predict the configurations of the most active compounds 3 on the basis of the configuration of endomorphin-2, a known MOR peptide ligand, validating the diversity-based approach to ligand discovery.</AbstractText>
            </Abstract>
            <Affiliation>Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Zhangjie</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrison</LastName>
                    <ForeName>Bryce A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verdine</LastName>
                    <ForeName>Gregory L</ForeName>
                    <Initials>GL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Org Lett</MedlineTA>
            <NlmUniqueID>100890393</NlmUniqueID>
            <ISSNLinking>1523-7052</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Alcohols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Alkenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Opioid, mu</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sulfur Radioisotopes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37589-80-3</RegistryNumber>
                <NameOfSubstance>Guanosine 5'-O-(3-Thiotriphosphate)</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Alcohols</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Alkenes</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Binding, Competitive</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">CHO Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Combinatorial Chemistry Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cricetinae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Guanosine 5'-O-(3-Thiotriphosphate)</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Opioid, mu</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stereoisomerism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Substrate Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sulfur Radioisotopes</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12605477</ArticleId>
            <ArticleId IdType="doi">10.1021/ol027237f</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
